Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...

Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects. Treatment with bleximenib and Venclexta ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

The diagnosis and management of invasive fungal infections in adult patients with hematological malignancies remains a ...